Neue Novavax: Anstieg nach 1:20 Re-Split
Seite 80 von 354 Neuester Beitrag: 10.06.24 19:00 | ||||
Eröffnet am: | 15.05.19 08:23 | von: moneywork4. | Anzahl Beiträge: | 9.84 |
Neuester Beitrag: | 10.06.24 19:00 | von: Unicorn71 | Leser gesamt: | 2.186.439 |
Forum: | Hot-Stocks | Leser heute: | 449 | |
Bewertet mit: | ||||
Seite: < 1 | ... | 77 | 78 | 79 | | 81 | 82 | 83 | ... 354 > |
Novavax (NVAX) is getting some momentum for its two-dose COVID-19 vaccine, starting with a series of emergency use fillings globally and the first authorization in Indonesia this month.
The company is on track to file with the U.S. Food and Drug Administration (FDA) by the end of the year, and has already called for a meeting with the agency to move forward, according to CEO Stanley Erck.
Erck told Yahoo Finance Live on Wednesday that the company expects to hear back from the FDA "very soon" and believes Novavax could receive up to five authorizations in the coming 6-8 weeks globally. But a majority of its distribution of actual doses is likely to start at the beginning of 2022.
We do expect to be able to ship to Indonesia, and perhaps one or two other countries before the end of the year. But the majority of our production is scheduled for the first quarter," Erck said.
The company has scaled up production and estimates it will have 2 billion doses per year starting next year.
"We're going to go from zero to a very large scale very quickly," Erck said.
Novavax has applied for emergency use with the World Health Organization, the U.K., Canada, Australia, New Zealand and has completed a rolling submission with the European Union. With a majority of the world's population still unvaccinated, Novavax is poised to play a role in areas that are especially hard to reach with mRNA vaccines, which have more demanding storage and shipping requirements.
The company's use of protein-based technology, compared to mRNA, has made it slower to ramp up production and testing. But its efficacy is comparable, boasting 90% efficacy against earlier strains of the virus.
The company has delayed its timeline for various reasons — including manufacturing and issues with partners — throughout the year. But Erck has said that the recent filings should signal an end to the series of delays.
While Pfizer (PFE)/BioNTech (BNTX) have received the most authorizations from the FDA for boosters and children, Moderna (MRNA) faces a delay in its authorization for the younger people, as the FDA needs time to analyze reports of myocarditis. The only other authorized vaccine in the U.S., from Johnson and Johnson (JNJ), has faced concerns over blood clots, and the FDA and Centers for Disease Control and Prevention recently authorized boosters encouraging use of mRNA vaccines, with studies showing they provide higher efficacy.
All told, Novavax has set its sights on the global market, and anticipates its first product will be in arms soon — including for booster doses in the U.S.
"We expect our authorization to include boosting throughout 2022 and beyond," Erck said.
https://finance.yahoo.com/news/...covid-19-vaccine-ceo-191036628.html
Nov 10, 2021
…stating that Novavax clinical trial participants from sites outside the US are considered fully vaccinated if they received the same product that was administered and independently evaluated in the US clinical trials. This means that participants in the UK and Mexico Phase 3 clinical trials are considered fully vaccinated if they received the full series of active Novavax COVID-19 vaccine.
…Novavax is preparing to submit the complete package for NVX-CoV2373, our protein-based COVID-19 vaccine to the US Food & Drug Administration (FDA) for emergency use authorization. The CDC guidance does not imply that the vaccine has been approved or authorized by FDA or is recommended by CDC or ACIP.
https://ir.novavax.com/...yRzBm_sA1ZjmlIg5Bx9YrS18yrK49VEUGMBCR40kw0M
https://www.politico.com/newsletters/...adds-new-lobbying-help-798830
"Protein basierter Impfstoff ist neu, die Wirksamkeit ist durch belegte Studien definitiv mindestens doppelt so lang"
Bitte um Angabe der Quelle(n)
Recht herzlichen Dank.
2. Was sind das für Meinungen aus der GME Community ? Auch hier konnte ich rein gar nichts recherchieren..
Sind das alles Vermutungen ?
Moderation
Zeitpunkt: 15.11.21 12:39
Aktion: Löschung des Beitrages
Kommentar: Regelverstoß - Unzureichende Quelleangabe
Zeitpunkt: 15.11.21 12:39
Aktion: Löschung des Beitrages
Kommentar: Regelverstoß - Unzureichende Quelleangabe
Da kommt als Antwort von 123456 nur „selbst recherchieren“
Quellangaben bereichern doch nur dieses Forum. Stellt euch vor, jemand kommt daher und stellt was negatives (z.b. Phase 3 Studie von Novavax ohne Erfolg, bekommt keine Zulassung in der EU und USA) hier ein ohne Quellangaben. Da würde doch auch jeder wissen wollen ob die Nachricht seriös ist oder nicht.
Nicht böse nehmen bitte, es hilft hier jedem weiter, die Nachrichten selbst zu bewerten.
Ich störe mich daran wenn hier User alles bis ins kleinste Detail vorgekaut haben wollen, ohne je selbst großartig als Info Lieferant in Erscheinung getreten zu sein, die hier Einschätzungen abgreifen und nassauern und andere die Arbeit machen lassen. Damit meine ich nicht Dich, damit das klar ist. Aber mancher der hier unsere Euphorie Bombe 123 angeht, sollte sich mal fragen wie groß sein Wirken selbst bisher war...
Und letztlich erschließt sich doch dem Mitleser des Forums mit der Zeit wer sich hier fundamental einbringt und wer Wunsch und Wirklichkeit nicht immer zu unterscheiden weiß...
Ich persönlich finde das Forum bisher jedenfalls sehr informativ und angenehm im Umgang miteinander. Hoffen wir das wir uns bald alle gegenseitig zu unserem Invest hier gratulieren dürfen!!!
https://de.advfn.com/nachrichten/...eficial-Ownership-4_86546568.html
https://stocktwits.com/SIBLY/message/405015049
https://stocktwits.com/Culkat/message/405067582